Atrium Therapeutics, Inc. Common Stock (RNA) earnings · rev $18.8M
These earnings events as JSON? API free 100/dayAtrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
This RNA earnings page is the cached print — revenue, income, and the latest exhibit — not a live call transcript.
Latest reported RNA revenue for 2025-12-31 was $18.8M. Net income was -$684.6M. Revenue was up 72.1% from 2024-12-31 to 2025-12-31. RNA currently screens at market cap $217.5M.
When the next RNA 8-K Item 2.02 lands, this page should move. Until then the SEC archive is the source.
The change that matters: Revenue was up 72.1% from 2024-12-31 to 2025-12-31. An earnings headline that ignores that move is noise.
Not investment advice. Full RNA research stays on the stock page; the tape stays on the quote page.
RNA earnings FAQ
What are RNA's latest revenue and net income?
Latest cached Atrium Therapeutics, Inc. Common Stock (RNA) revenue for Dec 31, 2025 was $18.8M. Net income was -$684.6M. Statements: https://lician.com/financials/rna
What is RNA's latest diluted EPS?
Latest cached Atrium Therapeutics, Inc. Common Stock (RNA) diluted EPS for Dec 31, 2025 was -$4.97.
What period does the latest RNA earnings print cover?
The latest cached Atrium Therapeutics, Inc. Common Stock (RNA) earnings print covers Dec 31, 2025. The prior cached period on this page is Dec 31, 2024.
How did RNA revenue change from the prior cached period?
Cached Atrium Therapeutics, Inc. Common Stock (RNA) revenue was up 72.1% from $10.9M (Dec 31, 2024) to $18.8M (Dec 31, 2025). Statements: https://lician.com/financials/rna
Where are RNA earnings listed?
Cached earnings facts for Atrium Therapeutics, Inc. Common Stock (RNA) are listed at https://lician.com/earnings/rna. Statements: https://lician.com/financials/rna
Not investment advice.